Our EVP and Chief People Officer, Heidi Manna was a guest on the #DigitalHRLeaders podcast and spoke to David Green 🇺🇦 about employee experience, people and culture at Jazz. Heidi talked about the importance of authentic employee listening and how it has shaped the way we create solutions within the organization, including the creation of our flexible working model, Jazz Remix, which leverages a mix of virtual and in person collaboration to successfully deliver against our objectives: https://bit.ly/3WyH9hZ #GreatPlacetoWork
About us
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.
- Website
-
http://www.jazzpharma.com
External link for Jazz Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Dublin
- Type
- Public Company
- Founded
- 2003
- Specialties
- Biopharmaceutical , innovation, research and development , great place to work, neuroscience , epilepsy, sleep disorders, oncology, and hematology
Locations
Employees at Jazz Pharmaceuticals
Updates
-
Today we recognize #WorldLungCancerDay and the impacts of #lungcancer, which affects millions of people worldwide every year. In particular, small cell lung cancer (#SCLC) brings a unique set of challenges to patients given it is often diagnosed at a late stage. We are committed to providing information and resources to patients with difficult-to-treat cancers like SCLC to help them navigate treatment on their own terms so they can live their lives more fully. Learn more on the Nothing Small About It website: https://lnkd.in/e6dt5Nay
-
Jazz announces second quarter 2024 financial results: https://bit.ly/4c9xNyI
-
We are continuing to explore new avenues to discover and develop meaningful treatment options to help improve the lives of people living with difficult-to-treat cancers. Visit our #PioneeringPathways page to learn more about our innovative research taking place in oncology and the experts behind this transformational approach: https://bit.ly/46Q5jIa
-
Our Executive Director, U.S. Medical Affairs, Epilepsy and Movement Disorders, Alison McReynolds discusses the importance of gathering expert perspectives to guide treatment recommendations. Establishing consensus is imperative in our mission to provide patients with consistent approaches to getting a diagnosis and managing their symptoms. https://bit.ly/46ki52s
-
-
Earlier this month, we attended the 9th Lennox-Gastaut Syndrome (LGS) Foundation Family and Professional Conference to connect with members of the Lennox-Gastaut syndrome (LGS) community and #epilepsy professionals from around the world. We are inspired by the strength and resilience of the LGS community and are committed to pursuing research approaches that address rare epilepsy syndromes.
-
-
In our continued efforts to prioritize corporate sustainability and social impact, our legal team members Sasha Willmott and Brian Clot recently participated pro bono in the Bright Tide’s Regenerative Farming accelerator program hosted by Hogan Lovells - HL BaSE. Teams were able to advise alongside fellow legal professionals on 9 different ventures – each one addressing sustainability and biodiversity loss. We are so proud that our team was able to contribute to making a difference for local communities and our environment. Read more about this pro-bono workshop: https://bit.ly/3WzCaP4
-
We’re pleased to welcome a new independent director, Laura Hamill, to the Jazz Board of Directors. Learn more: https://lnkd.in/eBDRrCPb
-
At Jazz, creating a great work experience for employees allows us to better serve our patients. Our EVP and Chief People Officer Heidi Manna spoke to David Green 🇺🇦 on the #DigitalHRLeaders podcast about the employee experience at Jazz and what makes us so unique, including our flexible working model, Jazz Remix. Heidi shared four elements of our people strategy and talked about the importance of really listening to employees, including how continuous dialogue helps to shape our working policies. https://lnkd.in/eBxWFHRJ #GreatPlacetoWork
-
#WorldBrainDay serves as a rallying point to increase education and advocacy efforts to help ensure that every individual has the knowledge and resources to prioritize and maintain their brain health. Today, we join the World Federation of Neurology and our global communities in the effort to champion quality neurology and promote brain health for all. Through strategic global advocacy partnerships, we continuously strive to better our understanding of patients’ needs in order to advance research around complex neurological disorders and develop medicines that are truly meaningful for people living with these conditions. By spreading awareness and fostering collaborations, we can collectively pave the way for a healthier future for those impacted.